Trial Information

Summary: The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the obsessive-compulsive disorder (OCD) of adult patients who have not responded to their OCD medication.

The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the obsessive-compulsive disorder (OCD) of adult patients who have not responded to their OCD medication. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer’s Disease. Memantine appears to work by regulating the activity of glutamate, one of the brain’s specialized messenger chemicals, which may play a role in OCD. All patients in the study will receive memantine; no one will receive placebo.

Patient Inclusion Criteria

• Adult age 18 and over
• Able to travel to Stanford weekly
• Suffering from moderate to severe obsessive-compulsive disorder
• Currently taking medication for OCD and receiving inadequate benefit

Patient Exclusion Criteria

• Receiving psychotherapy for OCD

If you would like to learn more about participating in this study, please send an e-mail message using the form below.